Recommendations on the use of COVID-19 vaccines (2021-09-28)

This evergreen document will be updated as COVID-19 vaccines are authorized and become available for use in Canada, and as evidence on these vaccines and COVID-19 evolves. This table summarizes the latest changes to this current version. Please refer to the Table of updates for a full list of updates to previous versions.

Data and Resources

Additional Info

Field Value
Last Updated April 17, 2026, 17:35 (UTC)
Created April 17, 2026, 17:35 (UTC)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2021-10-22 00:00:00
open_canada_keywords {"fr": ["Recommandations", "utilisation", "vaccins", "contre", "la COVID-19", "2021", "September", "Vaccins", "immunisation", "Comité", "consultatif", "national", "immunisation", "CCNI", "Déclarations", "publications", "Méthodologie", "Épidémiologie", "Résumé", "facteurs", "risque", "liés", "complications", "sévères", "attribuables", "risque", "accru", "exposition", "Vaccins", "Préparations", "utilisation", "approuvée", "Tableau", "Vaccins", "contre", "utilisation", "approuvée", "Efficacité", "potentielle", "efficacité", "réelle", "Immunogénicité", "Administration", "vaccins", "Calendrier", "immunisation", "vaccin", "COVID", "Dépistage", "sérologique", "Conditions", "entreposage", "Administration", "concomitante", "autres", "vaccins", "Innocuité", "manifestations", "cliniques", "inhabituelles", "MCI", "Populations", "spéciales", "Contre-indications", "précautions", "Ingrédients", "associés", "réactions", "allergiques", "autres", "produits", "Interactions", "médicamenteuses", "Produits", "sanguins", "immunoglobulines", "humaines", "moment", "immunisation", "Recommandations", "Résumé", "considérations", "vaccins", "utilisation", "autorisée", "disponible", "Considérations", "matière", "vaccination", "selon", "types", "vaccins", "disponsibles", "approuvée", "Priorités", "matière", "recherche", "Questions", "liées", "surveillance", "Force", "recommandations", "Comirnaty", "Pfizer-BioNTech", "Efficacité", "première", "apparition", "maladie", "symptomatique", "après", "dose", "avant", "la deuxième", "dose", "participants", "16 ans", "plus", "symptomatique", "adolescents", "12 à 15 ans", "Spikevax", "Moderna", "Vaxzevria", "AstraZeneca", "15 jours", "dosage", "ensemble", "efficacité", "de base", "DS/DS", "séronégatif", "apparition", "hospitalisation", "intervalle", "ensemble", "efficacité", "potentielle", "infection", "asymptomatique", "Janssen", "confirmée", "modérée", "sévère", "critique", "se manifestant", "14 jours", "28 jours", "après la vaccination", "ensemble", "conforme", "protocole", "Séquençage", "génétique", "variant", "préoccupant", "septembre", "décembre", "2020", "pays", "comptant plus", "de 100 cas", "PCR", "centrale", "sites", "locaux", "confirmés", "manière", "centralisée", "centralisée", "sérologique", "ensemble", "protocole", "évènements", "indésirables", "locaux", "sollicités", "administration", "vaccins", "essais cliniques"], "en": ["Vaccines", "immunization", "National", "Advisory", "Committee", "Immunization", "NACI", "Statements", "publications", "Recommendations", "use", "COVID-19", "vaccines", "Methods", "Epidemiology", "Summary", "risk", "factors", "severe", "outcomes", "COVID", "increased", "exposure", "Preparations", "authorized", "Canada", "efficacy", "effectiveness", "Immunogenicity", "administration", "schedule", "serological", "testing", "Storage", "requirements", "Concomitant", "administration", "other", "safety", "adverse", "events", "following", "AEFI", "Special", "populations", "Contraindications", "precautions", "Ingredients", "associated", "allergic", "reactions", "products", "Drug", "interactions", "Blood", "products", "human", "immunoglobulin", "timing", "immunization", "Recommendations", "Vaccination", "considerations", "types", "Research", "priorities", "Surveillance", "issues", "Strength", "NACI", "Clinical", "trial", "evidence", "Pfizer-BioNTech", "Comirnaty", "against", "first occurrence", "symptomatic", "disease", "after dose 1", "before dose 2", "participants", "16 years", "age and older", "adolescents", "12 to 15 years", "Moderna", "Spikevax", "AstraZeneca", "Vaxzevria", "Estimates", "vaccine", "efficacy", "against", "first", "occurrence", "confirmed", "15 days", "dosing", "interval", "SD/SD", "seronegative", "baseline", "set", "hospitalization", "asymptomatic", "infection", "Janssen", "14 days", "28 daysm post-vaccination", "per-protocolm", "Genetic", "sequencing", "results", "VOC", "September-December", "2020", "symptomatic", "by country", "for countries", "greater", "100 moderate", "to severe", "critical cases", "centrally", "in-country", "PCR-confirmed", "cases", "moderate"]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr Recommandations sur l’utilisation des vaccins contre la COVID-19 [2021-09-28]
update_frequency unknown